The Role of Type III Interferons in Hepatitis C Virus Infection and Therapy

被引:30
作者
Bruening, Janina [1 ]
Weigel, Bettina [1 ]
Gerold, Gisa [1 ]
机构
[1] Ctr Expt & Clin Infect Res TWINCORE, Inst Expt Virol, Hannover, Germany
关键词
ANTIVIRAL SIGNALING PROTEIN; REGULATORY FACTOR FAMILY; GENOME-WIDE ASSOCIATION; INNATE IMMUNE-RESPONSE; IFN-LAMBDA RECEPTOR; NF-KAPPA-B; GENE-EXPRESSION; STIMULATED GENES; SPONTANEOUS CLEARANCE; GLOBAL EPIDEMIOLOGY;
D O I
10.1155/2017/7232361
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The human interferon (IFN) response is a key innate immune mechanism to fight virus infection. IFNs are host-encoded secreted proteins, which induce IFN-stimulated genes (ISGs) with antiviral properties. Among the three classes of IFNs, type III IFNs, also called IFN lambdas (IFNLs), are an essential component of the innate immune response to hepatitis C virus (HCV). In particular, human polymorphisms in IFNL gene loci correlate with hepatitis C disease progression and with treatment response. To date, the underlying mechanisms remain mostly elusive; however it seems clear that viral infection of the liver induces IFNL responses. As IFNL receptors show a more restricted tissue expression than receptors for other classes of IFNs, IFNL treatment has reduced side effects compared to the classical type I IFN treatment. In HCV therapy, however, IFNL will likely not play an important role as highly effective direct acting antivirals (DAA) exist. Here, we will review our current knowledge on IFNL gene expression, protein properties, signaling, ISG induction, and its implications on HCV infection and treatment. Finally, we will discuss the lessons learnt from the HCV and IFNL field for virus infections beyond hepatitis C.
引用
收藏
页数:12
相关论文
共 134 条
[1]   Association of the IFNL4-ΔG Allele With Impaired Spontaneous Clearance of Hepatitis C Virus [J].
Aka, Peter V. ;
Kuniholm, Mark H. ;
Pfeiffer, Ruth M. ;
Wang, Alan S. ;
Tang, Wei ;
Chen, Sabrina ;
Astemborski, Jacquie ;
Plankey, Michael ;
Villacres, Maria C. ;
Peters, Marion G. ;
Desai, Seema ;
Seaberg, Eric C. ;
Edlin, Brian R. ;
Strickler, Howard D. ;
Thomas, David L. ;
Prokunina-Olsson, Ludmila ;
Sharp, Gerald B. ;
O'Brien, Thomas R. .
JOURNAL OF INFECTIOUS DISEASES, 2014, 209 (03) :350-354
[2]   Hepacivirus NS3/4A Proteases Interfere with MAVS Signaling in both Their Cognate Animal Hosts and Humans: Implications for Zoonotic Transmissions [J].
Anggakusuma ;
Brown, Richard J. P. ;
Banda, Dominic H. ;
Todt, Daniel ;
Vieyres, Gabrielle ;
Steinmann, Eike ;
Pietschmann, Thomas .
JOURNAL OF VIROLOGY, 2016, 90 (23) :10670-10681
[3]   Control of Hepatitis C Virus Replication in Mouse Liver-Derived Cells by MAVS-Dependent Production of Type I and Type III Interferons [J].
Anggakusuma ;
Frentzen, Anne ;
Guerlevik, Engin ;
Yuan, Qinggong ;
Steinmann, Eike ;
Ott, Michael ;
Staeheli, Peter ;
Schmid-Burgk, Jonathan ;
Schmidt, Tobias ;
Hornung, Veit ;
Kuehnel, Florian ;
Pietschmann, Thomas .
JOURNAL OF VIROLOGY, 2015, 89 (07) :3833-3845
[4]   Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo [J].
Ank, N ;
West, H ;
Bartholdy, C ;
Eriksson, K ;
Thomsen, AR ;
Paludan, SR .
JOURNAL OF VIROLOGY, 2006, 80 (09) :4501-4509
[5]   An important role for type III interferon (IFN-λ/IL-28) in TLR-induced antiviral activity [J].
Ank, Nina ;
Iversen, Marie B. ;
Bartholdy, Christina ;
Staeheli, Peter ;
Hartmann, Rune ;
Jensen, Uffe B. ;
Dagnaes-Hansen, Frederik ;
Thomsen, Allan R. ;
Chen, Zhi ;
Haugen, Harald ;
Klucher, Kevin ;
Paludan, Soren R. .
JOURNAL OF IMMUNOLOGY, 2008, 180 (04) :2474-2485
[6]  
[Anonymous], GUID SCREEN CAR TREA
[7]   IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4 [J].
Antaki, N. ;
Bibert, S. ;
Kebbewar, K. ;
Asaad, F. ;
Baroudi, O. ;
Alideeb, S. ;
Hadad, M. ;
Abboud, D. ;
Sabah, H. ;
Bochud, P. -Y. ;
Negro, F. .
JOURNAL OF VIRAL HEPATITIS, 2013, 20 (01) :59-64
[8]   Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C [J].
Asselah, T. ;
Bieche, I. ;
Narguet, S. ;
Sabbagh, A. ;
Laurendeau, I. ;
Ripault, M-P ;
Boyer, N. ;
Martinot-Peignoux, M. ;
Valla, D. ;
Vidaud, M. ;
Marcellin, P. .
GUT, 2008, 57 (04) :516-524
[9]  
Au-Yeung Nancy, 2013, JAKSTAT, V2, pe23931, DOI 10.4161/jkst.23931
[10]   IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction [J].
Bibert, Stephanie ;
Roger, Thierry ;
Calandra, Thierry ;
Bochud, Murielle ;
Cerny, Andreas ;
Semmo, Nasser ;
Duong, Francois H. T. ;
Gerlach, Tilman ;
Malinverni, Raffaele ;
Moradpour, Darius ;
Negro, Francesco ;
Muellhaupt, Beat ;
Bochud, Pierre-Yves .
JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (06) :1109-1116